Neal R. Cutler, M.D.
Dr. Neal Cutler is currently the CEO of Worldwide Clinical Trials, a global CRO that offers a full range of product development services to the pharmaceutical and biotechnology industries. Before this position, he was founder and director of California Clinical Trials from 1987-1999, which was one of the largest Phase I–III clinical pharmacology and investigational sites in the United States. This was expanded into a global CRO, also named Worldwide Clinical Trials, which he successfully merged into a subsidiary of UnitedHealth Group Inc.
From 2000-2006, Dr. Cutler founded and served as president and CEO of Alamo Pharmaceuticals, LLC. During this time, Dr. Cutler also developed and obtained FDA approval for a new drug to treat schizophrenia, FazaClo®, which is currently on the market today. He successfully merged Alamo into Avanir Pharmaceuticals in 2006.
Dr. Cutler is a board-certified psychiatrist and board-qualified in both neurology and clinical pharmacology. He was active at the National Institutes of Health (NIH) for over nine years, and served as deputy clinical director of the National Institute on Aging. He was previously president of the American Foundation for Clinical Pharmacology, and currently serves on a special emphasis panel review committee for the National Institute on Aging for the NIH.
Dr. Cutler has been instrumental in the design and clinical development of nearly 200 compounds in numerous therapeutic areas, with particular expertise in central nervous system disorders. He developed the revolutionary “dynabridge” and “bridging” study methodologies, which made feasible the study of the dynamic activity of a compound in the brain, and facilitated the rapid and effective development of a number of subsequent compounds.
Dr. Cutler has given several hundred international and national presentations in the fields of aging, clinical pharmacology and drug development. He has authored over 278 publications, including 9 books on the topics of clinical pharmacology, aging, Alzheimer’s disease, schizophrenia, anxiety disorders and diabetes.